Medpace (NASDAQ:MEDP) CEO August Troendle Sells 15,971 Shares of Stock

Medpace Holdings, Inc. (NASDAQ:MEDP) CEO August Troendle sold 15,971 shares of the firm’s stock in a transaction that occurred on Tuesday, September 15th. The shares were sold at an average price of $620.84, for a total transaction of $9,915,435.64. Following the completion of the sale, the chief executive officer owned 523,923 shares in the company, valued at $325,272,355.32. The trade was a 2.96% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Medpace Trading Down 0.2%

MEDP opened at $615.18 on Friday. The business’s 50 day moving average is $584.38 and its 200-day moving average is $509.80. The stock has a market cap of $17.17 billion, a PE ratio of 36.06, a price-to-earnings-growth ratio of 2.75 and a beta of 1.15. Medpace Holdings, Inc. has a twelve month low of $373.00 and a twelve month high of $677.90.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings data on Wednesday, July 22nd. The company reported $4.25 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.98 by $0.27. The business had revenue of $707.33 million during the quarter, compared to analyst estimates of $689.51 million. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The business’s revenue for the quarter was up 17.2% compared to the same quarter last year. During the same period in the prior year, the company posted $3.10 EPS. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. As a group, analysts forecast that Medpace Holdings, Inc. will post 17.54 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the stock. TD Cowen lifted their price objective on shares of Medpace from $419.00 to $492.00 and gave the company a “hold” rating in a research note on Friday, July 24th. Weiss Ratings upgraded shares of Medpace from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday, August 12th. BMO Capital Markets raised their target price on shares of Medpace from $400.00 to $600.00 and gave the company a “market perform” rating in a research note on Friday, July 24th. Truist Financial boosted their price target on shares of Medpace from $462.00 to $609.00 and gave the stock a “hold” rating in a research report on Friday, July 24th. Finally, Mizuho boosted their price target on shares of Medpace from $586.00 to $665.00 and gave the stock an “outperform” rating in a research report on Friday, July 24th. Three research analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $595.20.

Institutional Trading of Medpace

A number of hedge funds and other institutional investors have recently modified their holdings of the company. BlackRock Inc. acquired a new position in Medpace in the second quarter worth approximately $1,323,047,000. Geode Capital Management LLC boosted its stake in shares of Medpace by 3.8% during the 4th quarter. Geode Capital Management LLC now owns 667,298 shares of the company’s stock worth $374,836,000 after acquiring an additional 24,625 shares in the last quarter. Wasatch Advisors LP boosted its stake in shares of Medpace by 19.4% during the 1st quarter. Wasatch Advisors LP now owns 773,931 shares of the company’s stock worth $371,634,000 after acquiring an additional 125,625 shares in the last quarter. Renaissance Technologies LLC grew its holdings in shares of Medpace by 8.3% in the 1st quarter. Renaissance Technologies LLC now owns 504,668 shares of the company’s stock worth $242,337,000 after acquiring an additional 38,760 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership grew its holdings in shares of Medpace by 19.4% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 375,033 shares of the company’s stock worth $210,637,000 after acquiring an additional 60,883 shares during the last quarter. Institutional investors own 77.98% of the company’s stock.

About Medpace

Medpace Holdings, Inc is a global contract research organization (CRO) that provides outsourced clinical development services to pharmaceutical, biotechnology and medical device companies. The company supports sponsors throughout the drug and medical product development process, from early-stage planning and clinical trial design through study execution, regulatory submission and post-marketing activities.

Its services include clinical trial management, clinical monitoring, data management, biostatistics, medical writing, pharmacovigilance, regulatory consulting and central laboratory services.